Comparison of efficacy of azilsartan with olmesartan in patients of hypertension: randomized controlled trial

Authors

  • Deeksha Sharma Department of Pharmacology, Dr. RPGMC, Tanda, Kangra, Himachal Pradesh, India
  • Atal Sood Department of Pharmacology, Dr. RPGMC, Tanda, Kangra, Himachal Pradesh, India
  • Dinesh Kansal Department of Pharmacology, Dr. RPGMC, Tanda, Kangra, Himachal Pradesh, India
  • Dhiraj Kapoor Department of Pharmacology, Dr. RPGMC, Tanda, Kangra, Himachal Pradesh, India
  • Akshay Sharma Department of Pharmacology, Dr. RPGMC, Tanda, Kangra, Himachal Pradesh, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20233190

Keywords:

Azilsartan, Olmesartan, Chlorthalidone hypertension

Abstract

Background: Azilsartan and olmesartan are members of ARBs, used in the management of hypertension. Objective was to evaluate efficacy of azilsartan with olmesartan in patients of hypertension.

Methods: A randomized, prospective, open label, comparative study was carried out in Pharmacology and Medicine department at Dr. RPGMC Kangra at Tanda, HP. The study stretched over one year and blood pressure was monitored at first, third and sixth month. Out of 69 patients, 35 patients in group A were prescribed tablet azilsartan 40 mg/day and 34 patients in group B patients were prescribed tablet olmesartan 20 mg/day. Tablet chlorthalidone 12.5 mg/day was add on in both the groups. Data was presented as mean+SD. Student’s t test was used and p value <0.05 was considered significant.

Results: In group A, systolic blood pressure (SBP) values improved from baseline of 153±10 mmHg to 111±18 mmHg (p<0.001) at 3 months and 109±6.1 mmHg (p<0.001) at 6 months and diastolic blood pressure (DBP) values from baseline of 87±7 mmHg to 67.1±4.6 mmHg (p<0.001) at 3 months and 67.6±2.5 mmHg (p < 0.001) at 6 months. In group B, SBP values improved from baseline of 154±8.5 mmHg to 127±3.6 mmHg (p<0.001) at 3 months and 123±4 mmHg (p<0.001) at 6 months and DBP values from baseline of 85±6.5mm Hg to 75.7±3.3 mmHg (p<0.001) at 3 months and 73±3.3 mmHg (p<0.001) at 6 months. On intergroup comparison improvement in hypertension was better in azilsartan group (p<0.001).

Conclusions: The study concluded that azilsartan is significantly better than olmesartan in controlling the hypertension.

References

High Blood Pressure Facts. Available at: https://blogs.cdc.gov/global/2015. Accessed on 24 July 2022.

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Available at: https://www.nhlbi. nih.gov/files/docs/guidelines/jnc7full.pdf. Accessed on 24 July 2022.

Timmer PB, Duncia JV, Carini DJ. Discovery of losartan, the first angiotensin II receptor antagonist. J Hum Hypertens. 1995;9(5):S3-18.

Dahlöf B, Devereux RB, Kjeldsen SE. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311):995-1003.

Sica D, White WB, Weber MA. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs. valsartan by ambulatory blood pressure monitoring. J Clin Hypertens. 2011;13(7):467-72.

Drugs used in blood pressure. Available at: https://www.accessdata.fda.gov. Accessed on 24 July 2022.

Grossman A, Grossman E. Blood pressure control in type 2 diabetic patients. Cardiovasc. Diabetol. 2017; 16(1):1-5.

Bahtiyar G, Gutterman D, Lebovitz H. Heart failure: a major cardiovascular complication of diabetes mellitus. Curr Diab Rep. 2016;16:116.

Lin JJ, Chang HC, Ku CT, Chen HY. Hydrochlorothiazide hypertension treatment induced metabolic effects in type 2 diabetes: a metaanalysis of parallel-design RCTs. Eur Rev Med Pharmacol Sci. 2016;20:2926-34.

Shahin MH, Johnson JA. Mechanisms and pharmacogenetic signals underlying thiazide diuretics blood pressure response. Curr Opin Pharmacol. 2016; 27:31-7.

Sica D, Bakris GL, White WB, Weber MA, Cushman WC, Huang P, et al. Blood pressure–lowering efficacy of the fixed‐dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clini Hypertens. 2012;14(5):284-92.

Takagi H, Mizuno Y, Niwa M, Goto SN, Umemoto T. A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction. Hypertens Res. 2014;37(5):432-7.

White WB, Cuadra RH, Lloyd E, Bakris GL, Kupfer S. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens. 2016;34(4):788.

Weber MA, Sever P, Juhasz A, Roberts A, Cao C. A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone. J Renin Angiotens Aldos Sys. 2018;19(3):147.

Sinha S, Chary S, Thakur P, Talluri L, Reddy VK, Agarwal M, et al. Evaluation of the Efficacy and Safety of Azilsartan in Adult Patients with Essential Hypertension: A Randomized, Phase-III Clinical Study in India. J Assoc Phys India. 2021;69(2):35-9.

Downloads

Published

2023-10-25

How to Cite

Sharma, D., Sood, A., Kansal, D., Kapoor, D., & Sharma, A. (2023). Comparison of efficacy of azilsartan with olmesartan in patients of hypertension: randomized controlled trial . International Journal of Basic & Clinical Pharmacology, 12(6), 805–809. https://doi.org/10.18203/2319-2003.ijbcp20233190

Issue

Section

Original Research Articles